China Pharma Holdings Inc. (CPHI) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for China Pharma Holdings Inc. (CPHI:NYSE), powered by AI.

Current Price
$0.93
P/E Ratio
-0.1
Market Cap
399,103
Sector
Healthcare
What is the China Pharma Holdings Inc. stock price forecast?

China Pharma Holdings Inc. is currently trading at $0.93. View real-time AI analysis on Alpha Lenz.

What is China Pharma Holdings Inc. insider trading activity?

View the latest insider trading data for China Pharma Holdings Inc. on Alpha Lenz.

What is China Pharma Holdings Inc.'s P/E ratio?

China Pharma Holdings Inc.'s P/E ratio is -0.1.

China Pharma Holdings Inc.

NYSE · CPHI
$0.93+0.40(+74.09%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about China Pharma Holdings Inc.'s future dividend policy...
Alpha Chat Insight

China Pharma Holdings Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -20.9%.

Ask for details

Company Overview

China Pharma Holdings Inc. is a provider of pharmaceutical products known for its focus on the development, production, and marketing of generic and specialty drugs. The company operates primarily within the healthcare and pharmaceutical sectors, contributing significantly to the medical supply chain. Its portfolio includes a diverse range of products that address common health needs such as antibiotics, cardiovascular medications, and pain relief, positioning it as a crucial player in providing affordable healthcare solutions. China Pharma Holdings Inc. is particularly impactful in the Chinese market, leveraging extensive research and development capabilities to introduce effective treatment options. The company's operations are not just limited to drug manufacturing; they also involve significant efforts in distribution to ensure widespread accessibility of their medicines. With an aging global population and increasing demand for cost-effective healthcare solutions, China Pharma plays a vital role in meeting these needs, enhancing the treatment landscape not only in China but also in other countries. By adhering to stringent quality standards and regulatory compliances, China Pharma Holdings Inc. reinforces its commitment to improving health outcomes across its operational markets.

CEOMs. Zhilin Li
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees224

Company Statistics

FY 2025

Profile

$399.10KMarket Cap
$4.14MRevenue
0.00Shares Out
224Employees

Margins

-3.18%Gross
-36.37%EBITDA
-74.53%Operating
-76.91%Pre-Tax
-76.91%Net

Valuation

-0.13P/E
0.02P/B
0.10EV/Sales
-2.61EV/EBITDA
36.25P/FCF

Growth (CAGR)

-20.03%Rev 3Yr
-17.53%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-13.89%ROA
-20.91%ROE
-13.45%ROIC

Financial Health

$345.11KCash & Cash Equivalents
$7.91MNet Debt
36.32%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

China Pharma Holdings Inc. (ticker: CPHI) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 224 employees. Market cap is $399,103.

The current price is $0.93 with a P/E ratio of -0.13x and P/B of 0.02x.

ROE is -20.91% and operating margin is -74.53%. Annual revenue is $4M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
China Pharma Holdings Inc. (CPHI) Stock Forecast 2026 $0.93 — Price, Financials & Analyst Targets | Alpha Lenz